新型抗帕金森病药物沙芬酰胺  

A novel antiparkinsonian drug,safinamide

作　　者：梁瑶 张蕾 曾灶昌 LIANG Yao;ZHANG Lei;ZENG Zao-chang(Department of Pharmacy,Shenzhen Guangming New District People＇s Hospital,Shenzhen 518000,China;Department of Pharmacy,the University of Hong Kong-Shenzhen Hospital,Shenzhen 518000,China)

机构地区：[1]深圳市光明新区人民医院药剂科,深圳518000 [2]香港大学深圳医院药学部,深圳518000

出　　处：《中国新药杂志》2018年第14期1603-1606,共4页Chinese Journal of New Drugs

摘　　要：沙芬酰胺是一种口服高选择性、可逆性单胺氧化酶B抑制剂,于2017年3月获美国FDA批准,作为辅助治疗手段与左旋多巴联合使用治疗运动症状控制不佳的帕金森病患者,这是十多年来美国首个获批用于治疗帕金森病的新化学实体药物。本文对其药效学、药动学、临床研究、适应证与用法用量、药物相互作用等方面进行综述。Safinamide is a highly selective and reversible oral MAO-B inhibitor. In March 2017,safinamide was approved by US FDA as adjunctive treatment to levodopa in Parkinson＇s disease（ PD） patients with fluctuating motor symptoms. It is the first new chemical entity drug to be approved for the treatment of PD in the last decade. In this paper,the pharmacodynamics,pharmacokinetics,clinical studies,indications and usage,and drug interactions of safinamide were reviewed.

关 键 词：沙芬酰胺 单胺氧化酶B抑制剂 帕金森病 运动症状 

分 类 号：R971[医药卫生—药品]